Pharmaceutical product withdrawal: Attributions of blame and its impact on trust

References 

1. Sorescu AB, Chandy RK, Prabhu JC. Sources and financial consequences of radical innovation: insights from pharmaceuticals. J Mark. 2003;67:82–102
2. PhRMA. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 [press release]. March 24, 2008.
3. Rowberg RE. Pharmaceutical research and development: a description and analysis of the process. In: Parvis EN, ed. The Pharmaceutical Industry: Access and Outlook. New York: Nova Sciences Publishers, Inc.; 2002. p. 88–111.
4. DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185
5. IMS Health. IMS Health reports U.S. prescription sales grew 3.8% in 2007, to $286.5 billion [press release]. March 12, 2008.
6. Bakke OM, Manocchia MA, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108–117
   • MEDLINE
   • CrossRef
7. Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–2220
   • MEDLINE
   • CrossRef
8. Friedman M, Woodcock J, Lumpkin M, Shuren J, Hass A, Thompson L. The safety of newly approved medicines: do recent market removals mean there is a problem?. JAMA. 1999;281(18):1728–1734
   • MEDLINE
   • CrossRef
9. Dawar N, Pillutla M. Impact of product-harm crises on brand equity: the moderating role of consumer expectations. J Mark Res. 2000;215–226
10. Folkes V. Recent attribution research in consumer behavior: a review and new directions. J Consum Res. 1988;14:548–565
11. Klein J, Dawar N. Corporate social responsibility and consumers' attributions and brand evaluations in a product-harm crisis. Int J Res Mark. 2004;21:203–217
12. Tufts Center for the Study of Drug Development . Drug safety withdrawals in the U.S. not linked to speed of FDA approval. Tufts Impact Rep. 2005;7(5):1–4
13. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med. 2006;166:1938–1942
    • MEDLINE
    • CrossRef
14. Okie S. Safety in numbers—monitoring risk in approved drugs. NEJM. 2005;352(12):1173–1176
15. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004;292(21):2647–2650
    • CrossRef
16. Food and Drug Administration. Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. White Paper; 2005 Nov 10.
17. Jarrell G, Peltzman S. The impact of product recalls on the wealth of sellers. J Polit Econ. 1985;93(31):512–536
18. Kwon B. When bad things happen to good companies. FSB: Fortune Small Bus. 2000;10(8):104–107
19. Dranove D, Olsen C. The economic side effects of dangerous drug announcements. J Law Econ. 1994;37:323–343
20. Ahmed P, Gardella J, Nanda S. Wealth effects of drug withdrawals on firms and their competitors. Financ Manage. 2002;21–41
21. Mayer RC, Davis JH, Schoorman FD. An integrative model of organizational trust. Acad Manage Rev. 1995;20:709–733
    • CrossRef
22. Hall M, Camacho F, Dugan E, Balkrishnan R. Trust in the medical profession: conceptual and measurement issues. Health Serv Res. 2002;37(5):1419–1439
    • MEDLINE
    • CrossRef
23. Weiner B. An Attributional Theory of Motivation and Emotion. New York: Springer-Verlag; 1986;
24. Folkes V. Consumer reactions to product failure: an attributional approach. J Consum Res. 1984;10:398–409
25. Rosenthal M, Schlesinger M. Not afraid to blame: the neglected role of blame attribution in medical consumerism and some implications for health policy. Milbank Q. 2002;80(1):41–95
    • MEDLINE
    • CrossRef
26. Su W, Tippins M. Consumer attributions of product failure to channel members and self: the impacts of situational cues. Adv Consum Res. 1998;25:139–145
27. Laufer D, Gillespie K. Differences in consumer attributions of blame between men and women: the role of perceived vulnerability and empathic concern. Psychol Mark. 2004;21(2):141–157
28. Holloway BB. The Role of Switching Barriers in the Online Recovery Process [doctoral dissertation]. Tuscaloosa: The University of Alabama; 2003.
29. McCollough MA, Berry LL, Yadav MS. An empirical investigation of customer satisfaction after service failure and recovery. J Serv Res. 2000;3:121–137
30. Smith AK, Bolton RN, Wagner J. A model of customer satisfaction with service encounters involving failure and recovery. J Mark Res. 1999;36:356–372
31. Dugan E, Trachtenberg F, Hall M. Development of abbreviated measures to assess patient trust in a physician, health insurer, and the medical profession. BMC Health Serv Res. 2005;5:64
    • MEDLINE
    • CrossRef
32. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 4th ed.. Boston: Allyn and Bacon; 2001;
33. Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159
    • CrossRef